证券代码：603590 证券简称：康辰药业 公告编号：临 2025-049 北京康辰药业股份有限公司 一、公司 2023 年限制性股票激励计划（简称 "本激励计划"）实施情况 （一）股权激励计划已履行的程序 1、2023 年 7 月 31 日，公司召开第四届董事会第四次会议、第四届监事会第 三次会议，审议通过《关于公司<2023 年限制性股票激励计划（草案）>及其摘要 的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》等议 案。公司独立董事就本激励计划相关议案发表了独立意见。公司监事会对本激励 计划相关事项进行核实并出具了相关核查意见。 关于公司 2023 年限制性股票激励计划预留授予 第一个限售期解除限售暨上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 190,000股。 本次股票上市流通总数为190,000股。 本次股票上市流通日期为2025 年 9 月 4 日。 2、2023 年 8 月 1 日至 20 ...

北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划首次授予部分 第二个解除限售期、预留授予部分第一个解除限售期 解除限售条件成就及回购注销事项的 法律意见书 国枫律证字[2023]AN138-7 号 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel） 010-88004488/66090088 传真（Fax): 010-66090016 北京国枫律师事务所 关于北京康辰药业股份有限公司 2023 年限制性股票激励计划首次授予部分 法律意见书 国枫律证字[2023] AN138-7号 致:北京康辰药业股份有限公司 根据本所与康辰药业签署的《律师服务协议书》,本所接受康辰药业的委托,担 任康辰药业本次股权激励计划的特聘专项法律顾问,并已出具了《北京国枫律师事 务所关于北京康辰药业股份有限公司 2023 年限制性股票激励计划(草案)的法律意 见书》《北京国枫律师事务所关于北京康辰药业股份有限公司 2023 年限制性股票激 励计划首次授予事项的法律意见书》《北京国 ...

Market Overview - The biopharmaceutical sector increased by 0.85% on August 29, with Kangchen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Biopharmaceutical Sector - Kangchen Pharmaceutical (603590) closed at 56.17, up 10.01% with a trading volume of 67,100 shares and a transaction value of 366 million [1] - Rongchang Biopharmaceutical (688331) closed at 90.88, up 8.35% with a trading volume of 166,100 shares [1] - Sanofi Biopharmaceutical (688336) closed at 52.60, up 8.01% with a trading volume of 89,900 shares [1] - Baipusais (301080) closed at 58.61, up 7.34% with a trading volume of 42,800 shares [1] - Wanzhe Co. (000534) closed at 17.70, up 6.31% with a trading volume of 382,900 shares [1] Top Losers in Biopharmaceutical Sector - Tibet Pharmaceutical (600211) closed at 47.16, down 3.42% with a trading volume of 193,800 shares and a transaction value of 912 million [2] - Wendi Pharmaceutical (688488) closed at 17.36, down 2.36% with a trading volume of 126,200 shares [2] - Chengda Biopharmaceutical (688739) closed at 27.90, down 2.35% with a trading volume of 50,700 shares [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 506 million from institutional investors, while retail investors saw a net inflow of 402 million [2] - The top stocks by net inflow from institutional investors included Rongchang Biopharmaceutical with a net inflow of 127 million [3] - Kangchen Pharmaceutical had a net inflow of 68 million from institutional investors, but also saw outflows from retail investors [3]

Investment Rating - The report maintains a "Recommended" investment rating for the company [1][9]. Core Insights - The company achieved a revenue of 461 million yuan in the first half of 2025, representing a year-on-year growth of 13.79%, and a net profit attributable to shareholders of 91 million yuan, up 14.95% year-on-year [4]. - The core product KC1036 has shown promising results in clinical trials, with an overall response rate (ORR) of 26.1% for single-agent treatment of esophageal squamous cell carcinoma (ESCC) [8]. - The company is actively investing in Uruy Cayman, with a planned investment of 150 million yuan to enhance its international collaboration in innovative and original drugs [8]. Financial Performance Summary - The company forecasts net profits of 133 million yuan, 177 million yuan, and 214 million yuan for 2025, 2026, and 2027 respectively, indicating a recovery in its core business and ongoing innovation pipeline [9]. - The gross margin is projected to remain stable around 89.7% for the coming years, with net profit margins improving from 5.1% in 2024 to 16.8% by 2027 [12]. - The company's total assets are expected to decrease slightly from 3,920 million yuan in 2024 to 3,723 million yuan in 2027, while maintaining a low debt ratio of around 9.7% by 2027 [11][12].

Group 1 - The A-share biopharmaceutical sector experienced a significant surge in the afternoon of August 29, with Rongchang Biopharmaceutical rising over 12% [2] - Maiwei Biopharmaceutical saw a sharp increase of 9% [2] - Kangchen Pharmaceutical previously hit the daily limit, while Sanofi and Wanzhe shares, as well as Sanyuan Gene, all rose over 6% [2]

Core Viewpoint - The innovative drug concept has seen a resurgence, with Haoyuan Pharmaceutical rising over 15%, and both Kangchen Pharmaceutical and Huahai Pharmaceutical hitting the daily limit up [1] Company Summary - Haoyuan Pharmaceutical experienced a significant increase in stock price, rising more than 15% [1] - Kangchen Pharmaceutical and Huahai Pharmaceutical both reached the daily trading limit, indicating strong market interest and investor confidence [1] Industry Summary - The innovative drug sector is witnessing renewed interest, reflected in the substantial stock price movements of key players [1]

Core Viewpoint - The innovative pharmaceutical stocks experienced a significant rebound, with Huahai Pharmaceutical and Kangchen Pharmaceutical both hitting the daily limit up, indicating strong market interest and investor confidence in the sector [1] Industry Summary - The National Medical Products Administration of China reported that the country's pharmaceutical industry ranks second globally, with approximately 30% of the world's innovative drugs currently under research [1] - Since the beginning of the 14th Five-Year Plan, a total of 387 pediatric drugs and 147 rare disease drugs have been approved for market, effectively addressing the medication needs of key populations [1] Company Summary - Huahai Pharmaceutical and Kangchen Pharmaceutical both reached the daily limit up, reflecting positive market sentiment towards their stock performance [1] - Other companies such as Puris, Duolai Pharmaceutical, Haoyuan Pharmaceutical, Huana Pharmaceutical, Medisi, Lifang Pharmaceutical, and Guangshengtang also saw stock increases, with some rising over 5% [1]

Financial Performance - Company reported total revenue of 461 million yuan for the first half of 2025, an increase of 13.79% year-on-year [1] - Net profit attributable to shareholders reached 91.05 million yuan, up 14.95% year-on-year [1] - In Q2 2025, total revenue was 249 million yuan, reflecting a year-on-year increase of 20.93% [1] - Q2 2025 net profit attributable to shareholders was 46.55 million yuan, a year-on-year increase of 23.97% [1] Profitability Metrics - Gross margin stood at 90.18%, an increase of 0.72% year-on-year [1] - Net margin was 20.9%, a decrease of 3.0% year-on-year [1] - Total selling, administrative, and financial expenses amounted to 271 million yuan, accounting for 58.72% of revenue, down 4.1% year-on-year [1] Key Financial Ratios - Earnings per share (EPS) increased to 0.58 yuan, a rise of 16.0% year-on-year [1] - Book value per share was 19.57 yuan, up 0.34% year-on-year [1] - Operating cash flow per share was -0.07 yuan, a significant decrease of 114.28% year-on-year [1] Balance Sheet Highlights - Cash and cash equivalents increased to 366 million yuan, a rise of 32.08% year-on-year [1] - Accounts receivable rose to 345 million yuan, an increase of 26.66% year-on-year [1] - Interest-bearing debt increased to 247 million yuan, up 62.45% year-on-year [1] Business Evaluation - Company’s return on invested capital (ROIC) was 0.42% last year, indicating weak capital returns [3] - Historical median ROIC since listing is 9.88%, suggesting better investment returns in the past [3] - The business model relies heavily on research and marketing efforts, necessitating further analysis of these drivers [3] Accounts Receivable Concerns - Accounts receivable to profit ratio has reached 817.81%, indicating potential issues with receivables management [3]

Group 1 - The monkeypox concept sector declined by 0.91%, ranking among the top declines in concept sectors, with leading decliners including Aladdin, Tsinghua Tongfang, and Hongyuan Pharmaceutical [1] - Among the 61 stocks in the monkeypox concept sector, 17 stocks saw price increases, with Kangchen Pharmaceutical, Botao Bio, and Yipin Hong leading the gains at 3.17%, 2.18%, and 1.82% respectively [1] - The monkeypox concept sector experienced a net outflow of 1.397 billion yuan from main funds today, with Han Yu Pharmaceutical seeing the largest outflow of 339 million yuan [2][3] Group 2 - The top gainers in the monkeypox concept sector included Kangchen Pharmaceutical, Jihigh Development, and Lepu Medical, with net inflows of 27.1 million yuan, 17.6 million yuan, and 12.5 million yuan respectively [4] - The stocks with the largest net outflows in the monkeypox concept sector included Han Yu Pharmaceutical, Zhongsheng Pharmaceutical, and Weixin Bio, with outflows of 339 million yuan, 114 million yuan, and 99.5 million yuan respectively [2][3] - The overall performance of the monkeypox concept sector reflects a challenging market environment, with significant capital outflows impacting stock prices [2][4]

Group 1 - The core viewpoint is that multiple companies are engaging in stock repurchase activities, with varying amounts proposed and completed [4] - Beijing Keri plans to repurchase up to 100 million yuan, while Haimu Star and Haike Xinyuan plan to repurchase 36 million yuan and 22 million yuan respectively [1] - Kangchen Pharmaceutical's repurchase plan was approved at the shareholders' meeting, with a maximum repurchase amount of 3.3228 million yuan [2] Group 2 - AoFei Entertainment and Yong'an Futures have reported repurchase progress, with amounts of 80.802 million yuan and 9.9985 million yuan respectively [3] - WuXi AppTec, Tongyu Heavy Industry, and Weihai Guangtai have completed repurchases, with the highest amounts being 1 billion yuan, 110 million yuan, and 59.9844 million yuan respectively [3] - On August 28, 27 companies released 28 stock repurchase-related updates, including 18 companies disclosing new repurchase plans, 1 company having its plan approved, 2 companies reporting progress, and 6 companies completing their repurchase plans [4]